About Encelo

We care about making it easier for patients to participate in research. 

Encelo was founded in 2017 by Dr Katia Nazmutdinova and Dr Natalie Grefenstette. During her PhD at University College London, Katia was studying urine-derived cells, extracted from patients affected by a rare genetic condition, Bardet-Biedl Syndrome.


Sample collection relies on patient-clinic sessions which can be infrequent sometimes only a couple are scheduled per year. This means that obtaining the patient sample size necessary for conclusive results can take a long time.  On top of this sometimes the sample collected can't be used because of the low success rates of cell culture initiation with conventional urine sampling and lab based centrifugation.

Katia realised that making it easier for patients to take part in research and also improving recovery rates of cells would unlock huge potential for urine-derived cells to advance academic research, renal toxicology testing, renal disease diagnosis and open up new possibilities for personalised medicine.

Encelo have received a lot of interest in the cell isolation capabilities of the Cell Catcher from academia, biotech and pharma sectors and is currently focused on the commercial development of the patent pending technology.

The Team

Dr Katia Nazmutdinova

CEO and Co-founder

Dr Zoltan Kis


Prior to her scientific training, Katia ran a video transfer services company in the US, which was sold for a profit in 2007 and exists to this day. A question, "What makes us human?” prompted her to study Human Genetics for almost a decade in UCL, London. After obtaining her PhD and concluding that other humans make us human, she returned to the commercial world, launching Encelo. 

Zoltan has over 5 years postdoc research experience and he has also been a part of international research consortia that relies on collaborations between multiple teams and requires excellent managerial skills. Zoltán obtained his PhD in Bioengineering from Imperial College London and has co-authored over 20 scientific and technical publications. He has been invited to present at international conferences and to join expert panels in bioprocessing.